Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the latar study
International Journal of Development Research
Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the latar study
Received 19th January, 2021; Received in revised form 28th February, 2021; Accepted 16th March, 2021; Published online 30th April, 2021
Copyright © 2021, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled: “Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the Latar study” published by Spooner et al. in Ophthalmology Retina. (Doi.org/101016/j.oret.2020.09.019), which assessed the 10-year outcomes in 293 neovascular age-related macular degeneration eyes treated with vascular endothelial growth factor agents. The authors concluded that eyes with neovascular age-related macular degeneration maintained starting visual acuity when treated with vascular endothelial growth factor inhibitors for 10 years. However, the validation, extrapolation, and generalizability of this finding can be made only by regression analyses including all the missing data referred to above by us in addition to the baseline characteristics already assessed in this study, serving to identify the potential prognosticators influencing the stabilization of the visual acuity over 10 years of follow-up after the initiation of treatment.
